Diabetic Peripheral Neuropathic Pain (DPNP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Diabetic Peripheral Neuropathic Pain (DPNP) Market Outlook

Thelansis’s “Diabetic Peripheral Neuropathic Pain (DPNP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Peripheral Neuropathic Pain (DPNP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Diabetic Peripheral Neuropathic Pain (DPNP) Overview

Peripheral neuropathic pain (PNP) is a distressing and enduring chronic pain syndrome that can manifest following damage or disease affecting the peripheral somatosensory nervous system or due to drug triggers. PNP causes vary and can be categorized based on whether nerve damage arises from systemic factors like diseases, toxins, or medications or localized secondary effects like trauma, surgery, or cancer. The signs and symptoms of PNP can fluctuate as the disease progresses and can be influenced by the patient’s emotional state and anxiety levels. Neuralgias typically exhibit characteristic episodic paroxysms, whereas other neuropathic pains may occur as isolated episodes or as increasing intensity attacks on top of a continuous pain background. Peripheral neuropathy encompasses various types, with risk factors contingent upon the underlying condition or the affected nerves. PNP can either be congenital or develop due to injury or illness. The most prevalent form of peripheral neuropathy is associated with diabetes, affecting approximately 60–70% of diabetic patients. The numerous causes of peripheral neuropathy can be categorized as hereditary, infectious, immunologic, metabolic, mechanical, cancer-related, toxic, or idiopathic. Neuropathic pain syndromes represent chronic pain disorders resulting from nervous system lesions or diseases that typically transmit pain signals. These conditions encompass various situations, including health conditions, specific medications, or trauma. However, in some instances, the cause remains unidentified, termed idiopathic neuropathy. The Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain (IASP) recommends tricyclic antidepressants, gabapentin or pregabalin, and the SNRIs venlafaxine or duloxetine as first-line treatments for neuropathic pain. Second-line options encompass tramadol, topical lidocaine, or high-concentration capsaicin. Strong opioids (Morphine and Oxycodone) and botulinum toxin-A (BTX-A) are included as third-line treatments for peripheral neuropathic pain. Cannabinoids and valproate receive weak recommendations against their use in neuropathic pain. Chronic neuropathic pain is more prevalent in women and individuals over 50, typically affecting areas like the lower back and limbs and the neck and upper limbs.

• The prevalence of peripheral neuropathy among adults with diabetes varies significantly, estimated to range from 6% to 51%. This wide range is influenced by factors such as age, duration of diabetes, glucose control, and whether the diabetes is type 1 or type 2.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Diabetic Peripheral Neuropathic Pain (DPNP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034